These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31647019)

  • 1. Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison.
    Collyer BS; Turner HC; Hollingsworth TD; Keeling MJ
    Parasit Vectors; 2019 Oct; 12(1):499. PubMed ID: 31647019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines.
    Alsallaq RA; Gurarie D; Ndeffo Mbah M; Galvani A; King C
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005544. PubMed ID: 28410369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations.
    Turner HC; Truscott JE; Bettis AA; Farrell SH; Deol AK; Whitton JM; Fleming FM; Anderson RM
    Parasit Vectors; 2017 Apr; 10(1):213. PubMed ID: 28454578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Geshiyaro Project: a study protocol for developing a scalable model of interventions for moving towards the interruption of the transmission of soil-transmitted helminths and schistosome infections in the Wolaita zone of Ethiopia.
    Mekete K; Ower A; Dunn J; Sime H; Tadesse G; Abate E; Nigussu N; Seife F; McNaughton E; Anderson RM; Phillips AE
    Parasit Vectors; 2019 Oct; 12(1):503. PubMed ID: 31665080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of community-wide, integrated mass drug administration strategies for schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study.
    Lo NC; Bogoch II; Blackburn BG; Raso G; N'Goran EK; Coulibaly JT; Becker SL; Abrams HB; Utzinger J; Andrews JR
    Lancet Glob Health; 2015 Oct; 3(10):e629-38. PubMed ID: 26385302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination.
    Kura K; Truscott JE; Toor J; Anderson RM
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007349. PubMed ID: 31166956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equity and efficiency in the scaled-up implementation of integrated neglected tropical disease control: the health economics protocol of the COUNTDOWN multicountry observational study in Ghana, Cameroon and Liberia.
    Woode ME; Khan JAM; Thomson R; Niessen LW;
    BMJ Open; 2018 Jun; 8(6):e020113. PubMed ID: 29961005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?
    Kura K; Hardwick RJ; Truscott JE; Anderson RM
    PLoS Negl Trop Dis; 2021 Dec; 15(12):e0009946. PubMed ID: 34851952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting.
    Bartsch SM; Hotez PJ; Hertenstein DL; Diemert DJ; Zapf KM; Bottazzi ME; Bethony JM; Brown ST; Lee BY
    Vaccine; 2016 Apr; 34(19):2197-206. PubMed ID: 27002501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desirable characteristics of a schistosomiasis vaccine: some implications of a cost-effectiveness analysis.
    Guyatt HL; Evans D
    Acta Trop; 1995 Jun; 59(3):197-209. PubMed ID: 7572426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration.
    Kura K; Collyer BS; Toor J; Truscott JE; Hollingsworth TD; Keeling MJ; Anderson RM
    Vaccine; 2020 Jun; 38(28):4379-4386. PubMed ID: 32418795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
    Flasche S; Jit M; Rodríguez-Barraquer I; Coudeville L; Recker M; Koelle K; Milne G; Hladish TJ; Perkins TA; Cummings DA; Dorigatti I; Laydon DJ; España G; Kelso J; Longini I; Lourenco J; Pearson CA; Reiner RC; Mier-Y-Terán-Romero L; Vannice K; Ferguson N
    PLoS Med; 2016 Nov; 13(11):e1002181. PubMed ID: 27898668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis.
    Lo NC; Gurarie D; Yoon N; Coulibaly JT; Bendavid E; Andrews JR; King CH
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E584-E591. PubMed ID: 29301964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human behaviour, cost-effectiveness analysis and research and development priorities: the case of a schistosomiasis vaccine.
    Evans DB; Guyatt HL
    Trop Med Int Health; 1997 Nov; 2(11):A47-54. PubMed ID: 9391522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neglected tropical diseases: comparison of the costs of integrated and vertical preventive chemotherapy treatment in Niger.
    Leslie J; Garba A; Boubacar K; Yayé Y; Sebongou H; Barkire A; Fleming FM; Mounkaila I; Adamou S; Jackou ML
    Int Health; 2013 Mar; 5(1):78-84. PubMed ID: 24029850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application.
    Fitzpatrick C; Fleming FM; Madin-Warburton M; Schneider T; Meheus F; Asiedu K; Solomon AW; Montresor A; Biswas G
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005037. PubMed ID: 27918573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human schistosomiasis: potential long-term consequences of vaccination programmes.
    Chan MS; Woolhouse ME; Bundy DA
    Vaccine; 1997 Oct; 15(14):1545-50. PubMed ID: 9330466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
    Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
    BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.